-21.2%
TMUS vs GSK
+14.9%
-36.1%
-33.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +3.1% | +5.0% | -1.9% | +2.3% |
| 7D | +7.5% | +4.9% | +2.5% | +6.7% |
| 30D | -3.3% | +9.9% | -13.2% | -4.4% |
| 3M | -9.7% | +0.2% | -9.8% | -10.0% |
| 6M | -17.2% | +2.3% | -19.5% | -17.4% |
| YTD | -20.3% | +7.1% | -27.4% | -22.9% |
| 1Y | -21.2% | +13.1% | -34.3% | -24.1% |
| All | -21.2% | +14.9% | -36.1% | -24.1% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling